{
    "nctId": "NCT04125277",
    "briefTitle": "The SONImage Study",
    "officialTitle": "SONImage Study: Can Molecular Imaging Predict Outcome to First-line Endocrine Treatment \u00b1 CDK 4/6 Inhibition in Advanced ER+ Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Progression-free survival after first line treatment (PFS1)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient is eligible and participates in the SONIA trial for ER+ MBC.\n2. Able to give written informed consent and to comply with the SONImage protocol.\n3. Documentation of histologically confirmed diagnosis of estrogen receptor (ER) expression \\>10% breast cancer based on local results. The receptor status can be determined on the primary tumor or on a tumor biopsy of a metastatic lesion.\n\nExclusion Criteria:\n\n1. A patient who meets the exclusion criteria of the SONIA trial (see SONIA protocol).\n2. Contra-indication for PET imaging.\n3. Use of estrogen receptor ligands (i.e. tamoxifen or fulvestrant) \u2264 5 weeks before FES-PET imaging.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}